found Documents: 783

Announcements & Press Releases, Regulatory Notice | 22 Aug 2017

Director's Share Dealing

1 item

London: Tuesday, August 22, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 4,000 American Depositary Shares of

Download Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 18 Aug 2017

Directors' Share Dealing

1 item

London: Friday, August 18, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Wencheng Capital Limited (“WCL”), a person closely

Download Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 15 Aug 2017

Directors' Share Dealing

1 item

London: Tuesday, August 15, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (�

Download Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 10 Aug 2017

Director’s Share Dealing

1 item

London: Thursday, August 10, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 1,807 American Depositary Shares of th

Download Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 7 Aug 2017

Directors' Share Dealing

1 item

London: Monday, August 7, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- (a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (“P

Download Announcement (PDF)

Announcements & Press Releases, Group | 31 Jul 2017

Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs

1 item

London: Monday, July 31, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the glob

Director's Share Dealing

Directors' Share Dealing

Directors' Share Dealing

Director’s Share Dealing

Directors' Share Dealing

Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs

Total Voting Rights

Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma

Blocklisting Six Monthly Return

Chi-Med to Announce 2017 Half-Year Financial Results

Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China

Director’s Share Dealing

Chi-Med Submits New Drug Application to CFDA for Fruquintinib in Advanced Colorectal Cancer

Chi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO

Chi-Med Presents Clinical Data at ASCO 2017 Annual Meeting

Total Voting Rights

Results of Annual General Meeting

Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017

Total Voting Rights

Vesting of awards under the Long Term Incentive Plan

Grant of Share Options under Share Option Scheme

2016 Annual Report and Notice of Annual General Meeting

Chi-Med Appoints Weiguo Su, Chief Scientific Officer, to Board of Directors

Chi-Med to host R&D Briefings on March 29 & 30, 2017

Directors’ Share Dealing

Grant of Awards under Long Term Incentive Plan

Publication of Form 20-F for the Year Ended December 31, 2016

Chi-Med Reports Final Results for the Year Ended December 31, 2016 and Updates on Key Clinical Programs

Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of the European Neuroendocrine Tumor Society

Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer

Chi-Med Appoints Graeme Jack as Independent Non-executive Director and Chairman of Audit Committee

Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma

Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia

Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

Chi-Med to Announce 2016 Final Results

Chi-Med Appoints Industry Veteran Karen Ferrante to Board of Directors

Chi-Med Appoints Industry Veteran Paul Carter to Board of Directors

Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer

Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China

Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017 Gastrointestinal Cancers Symposium

Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China

Total Voting Rights

Blocklisting Six Monthly Return

Director’s Share Dealing

Director’s Share Dealing

Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting

Exercise of Share Options by a Person Discharging Managerial Responsibilities

Total Voting Rights

Director’s Share Dealing

Chi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”)